RHS is a developer of sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.
Published clinical studies have shown that a primary reason for IVF failure is the embryo having the wrong number of chromosomes, which is known as aneuploidy. One of the most significant recent advances to improve IVF success rates has been the introduction of advanced Pre-implantation Genetic Screening (PGS), where embryos are screened to determine whether they have the correct number of chromosomes before being selected for IVF transfer.
Specifically developed to offer an integrated, easy to use and interpret, price competitive product, RHS’s EmbryoCellect™ is a Pre-implantation Genetic Screening kit designed to increase the chance of a successful IVF cycle.
RHS recently listed on the Australian Stock Exchange (ASX:RHS). Prior to its listing, the company received over $1 million in grants from both the Australian and South Australian Governments and raised $5.5 million in venture capital investment.
RHS develops sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.Read More
LBT Innovations is a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories.Read More
Repromed is an IVF clinic that offers a complete range of highly personalised care, support and fertility treatment options.Read More
GroPep Bioreagents Pty Ltd manufactures and sells growth factors, antibodies and related proteins to university, institutional and industrial researchers.Read More